CBDNewsBreaks Archive - Page 20 of 278

TuesdayDec 21, 2021 2:52 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies that evidenced effective, sustained and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approvals for the protocols around its fourth hypertension study, HYPER-H21-4, which is just one of the many planned studies slated for 2022. “Others include HOR-A22-1, a pharmacokinetic study…

FridayDec 17, 2021 2:49 pm

CBDNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Focused on Florida Ahead of ‘Massive Medical Marijuana Boom’

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis sector operator, is off to a strong start in building its high-quality flower resource for product inventory at dispensaries throughout Florida. The company has been working to launch growing operations at its Apopka, Florida-based cultivation location, adding 19,200 square feet of production expected to deliver $30 million in annual revenues. The pods were approved by the state health department’s Office of Medical Marijuana Use (“OMMU”) with licensing granted just before Halloween, with five already in use for plant growth at that time with the remainder fast-tracked for output.…

TuesdayDec 14, 2021 2:18 pm

CBDNewsBreaks – Marijuana Company of America Inc.’s (MCOA) Strong Performance Reflects Ability to Execute on Diversification Strategy

Marijuana Company of America (OTC: MCOA) is a diversified holding company that is looking to grow its business and further establish itself in the legalized cannabis THC, hemp and cannabidiol (“CBD”) industries. MCOA recently achieved the highest quarterly revenue in its history and expects to drive continued growth across the entire business. “As part of the financial results for three months ended Sept. 30, 2021 (‘Q3 2021’), the company reported $442,178 in revenue, up from $53,195 in revenue reported in Q3 2020. This represented a 731% year-on-year increase. In addition, the company’s gross profits grew by 297%, from $16,025 reported…

MondayDec 13, 2021 1:17 pm

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Looking to Further Increase Share in Global Cannabis, Wellness Markets

Flora Growth Corp. (NASDAQ: FLGC), a company guided by the mission to build a connected, design-led collective of plant-based wellness and lifestyle brands that provide customers with a one-of-a-kind experience, recently announced it had closed the acquisition of Vessel Brand Inc., an industry leader in cannabis consumer technology. “This marks the addition of an exceptional brand builder with a proven track record of not only launching successful cannabis-related brands but also capturing market share in the rapidly-expanding United States cannabis landscape,” reads a recent article. “When making the announcement, Luis Merchan, the president and CEO of Flora Growth, noted, ‘With…

MondayDec 13, 2021 12:54 pm

CBDNewsBreaks – RYAH Group Inc. (CSE: RYAH) Unearthing Breakthrough Discoveries That Will Reshape Understanding of Plant-Based Medicines

RYAH Group (CSE: RYAH) is a leading data technology company in plant-based medicine committed to providing valuable insight and transforming patient care through big data and artificial intelligence. According to a recent article, which contains excerpts from a RYAH blog post, “The company is working to unearth breakthrough discoveries that will reshape the understanding of plant-based medicines.” In the blog post, for instance, RYAH provided an overview of the United Kingdom’s legal cannabis market, observing that “market analysts continue to place high hopes on the potential of the U.K. market. Yet, in its current form, there remains significant room for…

ThursdayDec 09, 2021 2:30 pm

CBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article…

TuesdayDec 07, 2021 2:52 pm

CBDNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Focusing on Continued Growth of Top-Line Revenue, Bottom-Line Results

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has officially entered the second phase of a three-phase development strategy that captures its expansion plan in Florida after installing, commissioning and loading five of 30 planned modular grow pods, which are already growing plants. RWB, through its subsidiary Red White & Bloom Florida LLC (“RWBFL”), is fast-tracking the remaining 25 pods. Collectively, the 30 pods will provide about 19,000 square feet of operating space with an expected yield of 10,000 pounds of high-quality flower annually. RWB anticipates this annual yield will generate $30 million in additional revenue. RWBFL also successfully…

MondayDec 06, 2021 1:32 pm

CBDNewsBreaks – Why Marijuana Company of America Inc. (MCOA) Is ‘One to Watch’

Marijuana Company of America (OTC: MCOA), which operates and invests in the cannabis sector directly, continues to grow its business. MCOA focuses on remaining fiscally conscious while further establishing itself in the legalized THC, hemp and CBD industries by offering unique exposure to the global cannabidiol sector. “The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners,” reads a recent article. “MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and…

MondayDec 06, 2021 1:20 pm

CBDNewsBreaks – Grapefruit USA Inc. (GPFT) Launches World’s Most Effectively Bioavailable CBD Delivery Cream

Grapefruit USA (OTCQB: GPFT), a premiere California-based cannabis and hemp company, today announced the official launch of the world’s first patented time-release, hemp-based CBD topical cream with boosted bioavailability, made possible by its proprietary Hourglass(TM) technology. Hourglass, a unique method for topical delivery of CBD, leverages a proprietary process that involves the grinding of CBD into nano-sized particles, substantially smaller than the width of a human hair, which allows for significantly higher bioavailability and absorption. “Over the last several months, our Hourglass product team has received extremely positive product feedback and internal reviews from our product testers and retail customers…

ThursdayDec 02, 2021 12:42 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

News and publishing service for CBD related companies

Contact us: 512.354.7000

CannabisNewsBreaks